High-Dose Dexamethasone May Be Harmful for Patients With COVID-19
Patients hospitalized with COVID-19 receiving supplemental oxygen had similar mortality outcomes with high- vs standard-dose dexamethasone, but evidence
Patients hospitalized with COVID-19 receiving supplemental oxygen had similar mortality outcomes with high- vs standard-dose dexamethasone, but evidence
A phase 3 trial demonstrates a high rate of complete response with cretostimogene, an investigational immunotherapy administered intravesically.
Compared with oncologists, urologists report more barriers to using standard of care treatment intensification in the first-line setting for metastatic
The geographic distribution of the malignancy in Finland provided a clue to an upward trend.
Increased levels can cause harm, but clinicians can help their patients focus on nourishing their body rather than fearing nutrients by staying current on guidelines…
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Investigators assessed the monosodium urate burden using 2 ultrasound scoring systems among patients with gout and compared their ability to predict flares.
Even after adjusting for socioeconomic factors, environmental factors independently tied to higher risk
US cancer survivors are more likely than the general population to have a mobility or self-care disability, a large study suggests.
Incorporating the chemokines in a model strongly detected clinically relevant rejections warranting biopsy and, if confirmed, antirejection treatment.